KYMERA THERAPEUTICS INC (KYMR)
Sector: Health Care
2026 Annual Meeting Analysis
KYMERA THERAPEUTICS INC · Meeting: June 24, 2026
Directors FOR
4
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Four Class III Directors
Director since 2015 with strong relevant life sciences and venture capital experience; KYMR's 3-year return of +147.4% outperforms the peer group median by +80.7 percentage points, well above the 50pp threshold required to trigger a withhold vote for strong-positive TSR companies, and no other policy flags apply.
CEO and director since 2019 with deep scientific and operational expertise as the company's founder; the TSR trigger does not apply given KYMR outperforms the peer group by +80.7 percentage points over three years, and the pay program is evaluated separately under Say on Pay.
Director since January 2022 with extensive biotech CEO experience at Alnylam and multiple public board roles; the TSR trigger does not apply, all meetings were attended at or above the 75% threshold, and no other policy flags are present.
Director since March 2021 with strong financial expertise as designated Audit Committee financial expert and CFO experience at multiple public life sciences companies; the TSR trigger does not apply and no other policy flags are present.
All four Class III director nominees receive a FOR vote. KYMR's 3-year total shareholder return of +147.4% outperforms the XBI — SPDR S&P Biotech ETF by +89.5 percentage points and the company's disclosed compensation peer group median by +80.7 percentage points, comfortably clearing the 65pp threshold required to trigger a withhold vote for companies with strong positive absolute returns. All directors attended 75% or more of meetings in 2025, none are overboarded under policy thresholds, no family relationships exist among directors or executives, all independent directors serve on appropriate committees, and the board includes a designated audit financial expert. The slate is well-qualified with relevant biotech, financial, and scientific expertise.
Say on Pay
✓ FORCEO
Nello Mainolfi, Ph.D.
Total Comp
$8,545,609
Prior Support
88%%
CEO total compensation of approximately $8.5 million is reasonable for the founder-CEO of a $6.7 billion clinical-stage biotech company and is well within expected benchmarks for the role, title, and market cap band. The pay structure is strongly performance-oriented — the proxy states that 92% of CEO pay and 86% of other named executive officer pay on average is 'at-risk,' with a meaningful mix of time-based stock options, performance-based stock options, and performance stock units tied to specific clinical milestones, satisfying the policy requirement that at least 50-60% of senior executive pay be variable. Pay-for-performance alignment is strong: KYMR's stock returned +147.4% over three years versus the XBI — SPDR S&P Biotech ETF's +57.9%, and the board awarded a 125% of target bonus payout reflecting genuine 2025 operational achievements including positive Phase 1b data for KT-621, initiation of Phase 2b studies, a new Gilead partnership, and $980.7 million raised. The company has a clawback policy in place, prior Say on Pay support was 88% (well above the 70% threshold), and there are no material governance concerns with the compensation program structure.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
8 yrs
Audit Fees
$1,377,253
Non-Audit Fees
$40,000
Ernst & Young LLP has served as Kymera's auditor since 2018 (approximately 8 years), well below the 25-year tenure threshold that would trigger a concern. Non-audit fees of $40,000 (tax work) represent only about 2.9% of audit fees of $1,377,253, far below the 50% ratio that would raise independence concerns. EY is a Big 4 firm fully appropriate for a company of KYMR's size and complexity, and there are no disclosed financial restatements.
Overall Assessment
Kymera Therapeutics' 2026 annual meeting ballot contains three proposals, all of which warrant a FOR vote. The company has delivered outstanding shareholder returns over the past three years (+147.4%), significantly outperforming both the XBI — SPDR S&P Biotech ETF and its disclosed compensation peer group, the director slate is well-qualified with no overboarding or attendance concerns, the auditor relationship is clean with minimal non-audit fees, and the executive compensation program is predominantly performance-based and aligned with the strong operational progress the company achieved in 2025.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing